MX360878B - Compuesto 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3il)- 3,4-dihidropirazino[2,3-b]pirazin-2(1h)-ona para usarse en el tratamiento de carcinoma de células escamosas de cabeza y cuello. - Google Patents

Compuesto 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3il)- 3,4-dihidropirazino[2,3-b]pirazin-2(1h)-ona para usarse en el tratamiento de carcinoma de células escamosas de cabeza y cuello.

Info

Publication number
MX360878B
MX360878B MX2014011077A MX2014011077A MX360878B MX 360878 B MX360878 B MX 360878B MX 2014011077 A MX2014011077 A MX 2014011077A MX 2014011077 A MX2014011077 A MX 2014011077A MX 360878 B MX360878 B MX 360878B
Authority
MX
Mexico
Prior art keywords
tor kinase
cancer
treatment
kinase inhibitors
cell carcinoma
Prior art date
Application number
MX2014011077A
Other languages
English (en)
Spanish (es)
Other versions
MX2014011077A (es
Inventor
Xu Shuichan
Mae Hege Kristen
Raymon Heather
Loraine Wong Lilly
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of MX2014011077A publication Critical patent/MX2014011077A/es
Publication of MX360878B publication Critical patent/MX360878B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2014011077A 2012-03-15 2013-03-14 Compuesto 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3il)- 3,4-dihidropirazino[2,3-b]pirazin-2(1h)-ona para usarse en el tratamiento de carcinoma de células escamosas de cabeza y cuello. MX360878B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261611361P 2012-03-15 2012-03-15
US201261715323P 2012-10-18 2012-10-18
PCT/US2013/031206 WO2013138557A1 (en) 2012-03-15 2013-03-14 Treatment of cancer with tor kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2014011077A MX2014011077A (es) 2014-10-14
MX360878B true MX360878B (es) 2018-11-21

Family

ID=48014336

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011077A MX360878B (es) 2012-03-15 2013-03-14 Compuesto 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3il)- 3,4-dihidropirazino[2,3-b]pirazin-2(1h)-ona para usarse en el tratamiento de carcinoma de células escamosas de cabeza y cuello.

Country Status (21)

Country Link
US (1) US20130245026A1 (cg-RX-API-DMAC7.html)
EP (1) EP2825170B1 (cg-RX-API-DMAC7.html)
JP (3) JP2015510891A (cg-RX-API-DMAC7.html)
KR (3) KR102122617B1 (cg-RX-API-DMAC7.html)
CN (2) CN104519885A (cg-RX-API-DMAC7.html)
AU (1) AU2013203153B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014022703A2 (cg-RX-API-DMAC7.html)
CA (1) CA2866872A1 (cg-RX-API-DMAC7.html)
EA (1) EA028414B1 (cg-RX-API-DMAC7.html)
ES (1) ES2677874T3 (cg-RX-API-DMAC7.html)
IL (1) IL234602B (cg-RX-API-DMAC7.html)
MX (1) MX360878B (cg-RX-API-DMAC7.html)
MY (1) MY174022A (cg-RX-API-DMAC7.html)
NI (1) NI201400111A (cg-RX-API-DMAC7.html)
NZ (1) NZ628416A (cg-RX-API-DMAC7.html)
PH (1) PH12014502029B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201405707XA (cg-RX-API-DMAC7.html)
TW (1) TWI583385B (cg-RX-API-DMAC7.html)
UA (1) UA114315C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013138557A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201406706B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA028414B1 (ru) * 2012-03-15 2017-11-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Лечение рака ингибиторами tor киназы
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
SG11201505446WA (en) 2013-01-16 2015-08-28 Signal Pharm Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
HK1221168A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法
US20140314673A1 (en) * 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
JP6382946B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
CA2908742C (en) * 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
MY189663A (en) 2013-04-17 2022-02-23 Signal Pharm Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
WO2014172425A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
EP3549940A1 (en) 2013-04-17 2019-10-09 Signal Pharmaceuticals, LLC Pharmaceutical formulations, of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
CN107474051B (zh) 2013-05-29 2020-10-30 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
EP3131552B1 (en) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2016010886A1 (en) 2014-07-14 2016-01-21 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2627352T3 (es) 2006-10-19 2017-07-27 Signal Pharmaceuticals, Llc Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas
RU2474582C2 (ru) 2006-10-19 2013-02-10 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Гетероарильные соединения, их композиции и их применение в качестве ингибиторов протеинкиназы
WO2010022243A1 (en) * 2008-08-20 2010-02-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemoprevention of head and neck squamous cell carcinomas
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
NZ599549A (en) 2009-10-26 2013-11-29 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
US20120028972A1 (en) * 2010-07-30 2012-02-02 Lilly Wong Biomarker assays for detecting or measuring inhibition of tor kinase activity
EA028414B1 (ru) * 2012-03-15 2017-11-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Лечение рака ингибиторами tor киназы

Also Published As

Publication number Publication date
WO2013138557A1 (en) 2013-09-19
TW201343168A (zh) 2013-11-01
NI201400111A (es) 2015-01-15
AU2013203153B2 (en) 2015-09-03
BR112014022703A2 (pt) 2021-05-04
NZ628416A (en) 2016-04-29
JP2019108368A (ja) 2019-07-04
PH12014502029A1 (en) 2014-11-24
ZA201406706B (en) 2016-05-25
TWI583385B (zh) 2017-05-21
JP2021102637A (ja) 2021-07-15
KR20140138927A (ko) 2014-12-04
EA028414B1 (ru) 2017-11-30
EA201491699A1 (ru) 2015-02-27
CA2866872A1 (en) 2013-09-19
IL234602B (en) 2020-05-31
SG11201405707XA (en) 2014-10-30
HK1201750A1 (en) 2015-09-11
CN104519885A (zh) 2015-04-15
MX2014011077A (es) 2014-10-14
CN108992446A (zh) 2018-12-14
KR20200070416A (ko) 2020-06-17
JP2015510891A (ja) 2015-04-13
MY174022A (en) 2020-03-04
ES2677874T3 (es) 2018-08-07
KR102122617B1 (ko) 2020-06-12
EP2825170B1 (en) 2018-05-09
KR20210071101A (ko) 2021-06-15
EP2825170A1 (en) 2015-01-21
IL234602A0 (en) 2014-11-30
UA114315C2 (uk) 2017-05-25
AU2013203153A1 (en) 2013-10-03
PH12014502029B1 (en) 2014-11-24
US20130245026A1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
PH12014502029B1 (en) Treatment of cancer with tor kinase inhibitors
PH12018502234B1 (en) Treatment of cancer with tor kinase inhibitors
MX2020004689A (es) Tratamiento del cancer con inhibidores de tor cinasa.
PH12017501500A1 (en) Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy
MX2015014591A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
PH12014502047A1 (en) Treatment of cancer with tor kinase inhibitors
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
PH12014502046A1 (en) Treatment of cancer with tor kinase inhibitors
HK1221144A1 (zh) 用於治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法
PH12015500867B1 (en) Treatment of prostate cancer with tor kinase inhibitors
MX384142B (es) Antagonista de unión al eje pd-1 e inhibidores de tigit para usarse en el tratamiento de cáncer.
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
EA201491695A1 (ru) Лечение рака ингибиторами tor-киназы

Legal Events

Date Code Title Description
FG Grant or registration